WO2007029677A1 - 組織再生用基材 - Google Patents
組織再生用基材 Download PDFInfo
- Publication number
- WO2007029677A1 WO2007029677A1 PCT/JP2006/317513 JP2006317513W WO2007029677A1 WO 2007029677 A1 WO2007029677 A1 WO 2007029677A1 JP 2006317513 W JP2006317513 W JP 2006317513W WO 2007029677 A1 WO2007029677 A1 WO 2007029677A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tissue regeneration
- cell growth
- growth factor
- regeneration substrate
- gelatin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/60—Materials for use in artificial skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
Definitions
- the present invention relates to a tissue regeneration substrate. Specifically, the present invention relates to an artificial dermis base material for regenerating skin tissue in acute skin defect wounds such as burns and trauma and chronic skin defect wounds such as pressure sores and ulcers.
- a method for producing an artificial dermis a method of freeze-drying a collagen sponge is generally used, and crosslinking is often performed for the purpose of controlling the rate of degradation and absorption in vivo.
- a certain growth factor for example, basic fibroblast growth factor (bFGF)
- bFGF basic fibroblast growth factor
- Non-patent Document 2 Kawai et al. Have shown that injecting bFGF-impregnated gelatin microspheres into artificial dermis promotes the sustained release effect of bFGF and the in vivo construction of skin tissue (non-) Patent Document 1). It has also been clarified that tissue construction is promoted by adding bF GF-impregnated gelatin microspheres in the production of cell-embedded cultured skin (Non-patent Document 2).
- bFGF basic fibroblast growth factor
- bFGF has an isoelectric point of 9.6, and is adsorbed by, for example, electrical interaction with gelatin having an isoelectric point of 5.0.
- bFGF is adsorbed on microspheres made of acidic gelatin (isoelectric point 5.0), and bFGF is gradually released in vivo by using the microspheres on which bFGF is adsorbed.
- this method requires a technique such as injecting bFGF to the base material after adsorbing bFGF to the microsphere, which is a fine particle, and is used in clinical settings. It was complicated and difficult to use.
- bFGF is easy to adsorb, and it is considered that an artificial dermis material is made with acidic gelatin and bFGF is adsorbed there. Because it is inferior due to invasion of cells, it is suitable for tissue regeneration. A substrate capable of adsorbing an appropriate amount of bFGF while allowing easy entry of surrounding cells is desired.
- Patent Document 2 describes that a medical base material containing gelatin and collagen as essential base material components and cross-linked by irradiation with ultraviolet rays is used for a cell culture carrier, cultured skin, and the like. Has been.
- Patent Document 1 Japanese Patent Laid-Open No. 2003-325652
- Patent Document 2 Japanese Patent Laid-Open No. 11-47258
- Non-patent literature l K. Kawai et al., Biomaterials, Vol. 21, p.489-499 (2000)
- Non-Patent Document 2 Sao et al., Journal of the Japan Burn Society, Vol. 29, p.24-30
- Non-Patent Document 3 Y. Tabata et al., J. Controlled Release, Vol. 31, p.189-199 (1994) Disclosure of Invention
- the present invention has a sustained release ability of cell growth factors such as basic fibroblast growth factor (bFGF).
- bFGF basic fibroblast growth factor
- an object of the present invention is to provide a tissue regeneration substrate that is easy for cells to enter and is suitable for tissue regeneration.
- a base material obtained by adding bFGF to a bioabsorbable porous base material containing collagen and gelatin is bFGF. It has been found that it has good sustained release properties and is suitable as a tissue regeneration substrate for regenerating skin tissue as soon as cells invade. Based on this knowledge, the present invention was completed through further research.
- the present invention provides the following tissue regeneration base material and method for producing the same.
- Item 1 A tissue regeneration substrate comprising a bioabsorbable porous substrate containing collagen and gelatin containing a cell growth factor.
- Item 2 The tissue regeneration substrate according to Item 1, wherein the bioabsorbable porous substrate has a gelatin content of 1 to 70% by weight.
- Item 3 The tissue regeneration substrate according to Item 1 or 2, wherein the cell growth factor is basic fibroblast growth factor (bFGF).
- bFGF basic fibroblast growth factor
- Item 4 Initial stage in which the amount of cell growth factor released into PBS after being immersed in 37 ° C phosphate buffered saline (PBS) for 3 days is impregnated in the tissue regeneration substrate Item 4.
- the tissue regeneration substrate according to any one of Items 1 to 3, which is 7% by weight or less based on the total amount of cell growth factors.
- Item 5 Initial stage in which the amount of cell growth factor released into PBS after being immersed in phosphate buffered saline (PBS) at 37 ° C for 7 days was impregnated in the tissue regeneration substrate Item 5.
- the tissue regeneration substrate according to any one of Items 1 to 4, which is 15% by weight or less based on the total amount of cell growth factors.
- Item 6 The tissue regeneration substrate according to any one of Items 1 to 5 having continuous pores having an average pore diameter of 10 to 500 / ⁇ ⁇ .
- Item 7 The tissue regeneration substrate according to any one of Items 1 to 6, which is decomposed and absorbed within 3 weeks in a living body.
- Item 8 A tissue regeneration substrate comprising a step of freeze-drying an aqueous mixture containing collagen and gelatin, a step of crosslinking the resulting dried product, and a step of incorporating a cell growth factor into the resulting crosslinked product Manufacturing method.
- the present invention is described in detail below.
- the tissue regeneration substrate of the present invention comprises a cell growth factor in a bioabsorbable porous substrate containing collagen and gelatin.
- the tissue regeneration base material of the present invention means a base material widely used in regenerative medicine, for example, a base material used in regenerative medicine such as skin, bone, cartilage, myocardium and fat. In particular, it is suitably used as a tissue regeneration substrate for skin (dermis), that is, an artificial dermis substrate.
- the bioabsorbable porous substrate used for the tissue regeneration substrate of the present invention contains collagen and gelatin as essential components.
- the gelatin is not particularly limited.
- gelatin derived from bones such as cows, pigs, chickens, and rabbits, tendons, and skins can be used.
- the gelatin is preferably acid-treated or alkali-treated. Acid-treated gelatin is positively charged, and alkali-treated gelatin is negatively charged.
- Various cell growth factors can be bound without being denatured by electrostatic binding. Therefore, good sustained release of cell growth factor (for example, bFGF) becomes possible.
- collagen those derived from the skin, tendon, etc. of cows, pigs, etc. are not particularly limited. From the standpoint of improving safety by eliminating antigenicity, fat collagen is preferred in which collagen is treated with an enzyme such as peptase to remove telopeptides as much as possible.
- an enzyme such as peptase to remove telopeptides as much as possible.
- the content of gelatin contained in the bioabsorbable porous substrate is about 1 to 70% by weight, preferably about 20 to 60% by weight, more preferably about 30 to 50% by weight. If the gelatin content is too high, it will be difficult for surrounding tissues to enter the bioabsorbable porous substrate. On the other hand, if the gelatin content is too low, electrostatic interaction between gelatin and cell growth factors will occur. Adsorption due to becomes weak and the sustained release performance decreases. Therefore, the content range is as described above. The effect of gelatin and collagen can be effectively demonstrated and high therapeutic effects can be obtained.
- the bioabsorbable porous substrate preferably has a porous structure because it becomes a substrate that regenerates the tissue three-dimensionally.
- the average pore diameter of the microscopic pores of the bioabsorbable porous substrate is a force that can select an optimum value depending on the tissue or organ to be regenerated, preferably about 10 to 500 / ⁇ ⁇ . Preferably, it is about 50 to 300 / ⁇ ⁇ . If it is less than 10 m, cells may not enter the bioabsorbable porous substrate, resulting in extremely inferior cell adhesion, or force that the adhered cells cannot extend three-dimensionally. If it exceeds 500 / zm, the cell density may be low, and the tissue or organ may not be regenerated.
- the tissue regeneration substrate of the present invention reflects the porous structure of the bioabsorbable porous substrate as it is.
- the tissue regeneration substrate of the present invention comprises a cell growth factor in a bioabsorbable porous substrate containing collagen and gelatin.
- the cell growth factor is not particularly limited as long as it promotes angiogenesis and enhances cell activity.
- a cell growth factor having an angiogenesis action specifically, a basic fibroblast growth factor (bFGF) ), Acidic fibroblast growth factor (aFGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), plasma-derived growth factor (PDGF), angiopoetin, and transforming growth factor (TGF). It is done.
- a particularly preferred embodiment of the present invention is bFGF.
- the content of the cell growth factor in the tissue regeneration base material of the present invention can be appropriately selected according to the target yarn and texture to be regenerated, and is not particularly limited. Preferably, for 1cm 2
- the tissue regeneration substrate of the present invention can stably and slowly release cell growth factors over a long period of time. It has an excellent sustained release performance.
- bFGF has an action of promoting angiogenesis and enhancing the activity of cells, but it is an unstable substance in the living body, and even if it is used in an aqueous solution state, there is almost no expected biological effect.
- bFGF can be released slowly and the action of bFGF can be stably maintained.
- the tissue regeneration substrate of the present invention has, for example, the amount of cell growth factor released into PBS after being immersed in 37 ° C phosphate buffered saline (PBS) for 3 days. It is characterized in that it is 7% by weight or less (preferably 6% by weight or less) with respect to the total amount of the initial cell growth factor impregnated in the substrate. Also, the amount of cell growth factor released into the PBS after being immersed in 37 ° C phosphate buffered saline (PBS) for 7 days The total amount of initial cell growth factors impregnated in the substrate 15% by weight or less (preferably 13% by weight or less). In particular, when the cell growth factor is bFGF, the above sustained release performance is exhibited with good reproducibility.
- tissue regeneration substrate of the present invention also serves as a bioabsorbable substrate containing collagen and gelatin, it is decomposed and absorbed within 3 weeks in vivo.
- the preferable lower limit of the moisture content of the tissue regeneration substrate is 90%, and the preferable upper limit is 99.8%.
- the water content of the bioabsorbable porous substrate corresponds to the degree of crosslinking of the bioabsorbable porous substrate, and the water content decreases as the degree of crosslinking increases. If the moisture content is less than 90%, the obtained tissue regeneration substrate may not have the flexibility suitable for transplantation. If it exceeds 99.8%, the obtained tissue regeneration substrate becomes a culture solution or buffer. In some cases, strength cannot be maintained. A more preferred lower limit is 95%, and a more preferred upper limit is 98%.
- the moisture content is based on the following formula.
- Moisture content (%) [(Ws-Wd) / Ws] X 100 (%)
- Ws represents the weight (wet weight) when the tissue regeneration substrate is immersed in phosphate buffered saline for 1 hour at 25 ° C
- Wd represents the adhesion prevention material using a vacuum dryer. It represents the weight when completely dried (dry weight).
- the tissue regeneration substrate of the present invention comprises a step of freeze-drying an aqueous mixture containing collagen and gelatin, a step of crosslinking the resulting dried body, and cell growth in the resulting crosslinked body. It is manufactured by a manufacturing method including a step of containing a factor.
- the above gelatin and collagen are mixed to form an aqueous solution, which is cast into a suitable mold and frozen at 40 to 80 ° C for 30 minutes to 2 hours.
- the frozen material is freeze-dried to produce a sponge-like bioabsorbable porous substrate.
- the obtained lyophilized product is subjected to a crosslinking treatment to produce a bioabsorbable porous substrate.
- a crosslinking treatment there are no particular limitations on the method of crosslinking the frozen dried product, and examples thereof include a thermal crosslinking method, a ⁇ -ray irradiation method, an ultraviolet irradiation method, an electron beam irradiation method, an X-ray irradiation method, and a chemical crosslinking method using a crosslinking agent. It is done. Among them, a chemical crosslinking method using a crosslinking agent is preferable because the entire substrate can be crosslinked so as to have a uniform degree of crosslinking.
- a freeze-dried product can be immersed in an aqueous solution containing a cross-linking agent such as dartalaldehyde to perform chemical cross-linking. Excess dartalaldehyde is removed by washing with water, and freeze-dried again if necessary to obtain a crosslinked bioabsorbable porous substrate.
- a cross-linking agent such as dartalaldehyde
- cell growth factor is contained in the obtained cross-linked substrate, and the method is not particularly limited.
- an aqueous solution containing cell growth factor is dropped onto the cross-linked body.
- Cell growth factor For example, the cross-linked product is impregnated with an aqueous solution containing. Then, you may provide a drying process further as needed.
- the tissue regeneration base material of the present invention (particularly, artificial dermal base material) can stably and slowly release cell growth factors and can easily enter cells, so that wound healing is promoted. The healing period can be greatly shortened.
- FIG. 1 is a graph showing the results of an in vitro bFGF sustained release test in Test Example 1
- FIG. 2 is a tissue slice image when the gelatin content of the sponge in Test Example 1 is 0% by weight.
- FIG. 3 is a tissue slice image when the gelatin content of the sponge in Test Example 1 is 10% by weight.
- FIG. 4 is a tissue section image when the gelatin content of the sponge in Test Example 1 is 30% by weight.
- FIG. 5 is a tissue slice image when the gelatin content of the sponge in Test Example 1 is 50% by weight.
- FIG. 6 is a tissue slice image when the gelatin content of the sponge in Test Example 1 is 100% by weight.
- Pig tendon-derived type I collagen and pig skin-derived gelatin were mixed to form an aqueous solution.
- An aqueous solution was placed in a mold and frozen at 40 ° C for 1 hour, and then freeze-dried to produce a sponge.
- Thermal crosslinking was performed by treating the sponge at 110 ° C under vacuum. Further, after thermal cross-linking, it was immersed in 0.2% dartalaldehyde and 0.05N acetic acid aqueous solution to carry out chemical cross-linking. Excess dartalaldehyde was removed by washing with water, and freeze-dried again to obtain a crosslinked collagen gelatin sponge. This crosslinked sponge was used in the subsequent in vitro sustained release test.
- the sponge used in the experiment had a gelatin content of 0, 10, 30, 50% by weight.
- the sustained release test was performed by immersing the sponge in PBS at 37 ° C, and quantifying bFGF released in PBS after 1, 3, 5, 7, and 9 days by the ELISA method.
- Table 1 and Fig. 1 show the ratio of the amount of bFGF released over the number of days elapsed when the weight of bFGF contained in each sponge after impregnation is 100, that is, the bFGF elution ratio (%).
- the sponge used in the experiment was a sponge having a gelatin content of 0, 10, 30, 50, or 100% by weight. This was made into a sponge having a diameter of 12 mm and a thickness of 3 mm, and bFGF aqueous solution 1001 was dropped on the sponge so as to be impregnated with 0 g of bFGF.
- Figures 2-6 show tissue slice images after 2 weeks of implantation of this sponge in the skin defect layer on the back of the guinea pig.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/065,979 US8889171B2 (en) | 2005-09-09 | 2006-09-05 | Tissue regeneration substrate |
BRPI0615905A BRPI0615905B8 (pt) | 2005-09-09 | 2006-09-05 | substrato para regeneração de tecido e método para produção do referido substrato |
AU2006288336A AU2006288336B2 (en) | 2005-09-09 | 2006-09-05 | Tissue regeneration substrate |
KR1020087007675A KR101224927B1 (ko) | 2005-09-09 | 2006-09-05 | 조직 재생용 기재 |
CA2619785A CA2619785C (en) | 2005-09-09 | 2006-09-05 | Sustained release of a cell growth factor from a tissue regeneration substrate comprising collagen and gelatin |
EP06797419.6A EP1923078B1 (en) | 2005-09-09 | 2006-09-05 | Tissue regeneration substrate |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-261840 | 2005-09-09 | ||
JP2005261840A JP5008284B2 (ja) | 2005-09-09 | 2005-09-09 | 組織再生用基材 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007029677A1 true WO2007029677A1 (ja) | 2007-03-15 |
Family
ID=37835797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/317513 WO2007029677A1 (ja) | 2005-09-09 | 2006-09-05 | 組織再生用基材 |
Country Status (9)
Country | Link |
---|---|
US (1) | US8889171B2 (ja) |
EP (1) | EP1923078B1 (ja) |
JP (1) | JP5008284B2 (ja) |
KR (1) | KR101224927B1 (ja) |
CN (1) | CN101257933A (ja) |
AU (1) | AU2006288336B2 (ja) |
BR (1) | BRPI0615905B8 (ja) |
CA (1) | CA2619785C (ja) |
WO (1) | WO2007029677A1 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9283302B2 (en) * | 2011-12-16 | 2016-03-15 | Cormatrix Cardiovascular, Inc. | Extracellular matrix encasement structures and methods |
EP2353547B1 (en) * | 2008-06-26 | 2018-01-17 | Nobelpharma Co., Ltd. | Agent for regenerating tympanic membrane or external auditory canal |
JP5396803B2 (ja) * | 2008-10-06 | 2014-01-22 | コニカミノルタ株式会社 | 細胞培養基材及び細胞培養方法 |
JP2010130913A (ja) * | 2008-12-02 | 2010-06-17 | Gunze Ltd | グルコース消費量測定による細胞成長因子の活性評価方法 |
JP2014030663A (ja) * | 2012-08-06 | 2014-02-20 | Gunze Ltd | 徐放性組織再生材料 |
JPWO2014115732A1 (ja) * | 2013-01-25 | 2017-01-26 | 富士フイルム株式会社 | 移植用人工真皮およびその製造方法 |
JP6429490B2 (ja) * | 2014-05-12 | 2018-11-28 | 多木化学株式会社 | コラーゲン線維架橋多孔体 |
JP6432967B2 (ja) * | 2014-05-12 | 2018-12-05 | 多木化学株式会社 | 溶解性コラーゲン線維多孔体 |
CN107849539A (zh) * | 2015-08-13 | 2018-03-27 | 富士胶片株式会社 | 多能干细胞的培养方法、培养容器的制造方法、培养容器以及细胞培养用支架材料 |
CN109311224B (zh) * | 2016-06-08 | 2020-12-29 | 富士胶片株式会社 | 明胶成型体的制造方法及明胶成型体 |
CN107126579A (zh) * | 2017-05-15 | 2017-09-05 | 中国科学院西北高原生物研究所 | 一种具有快速止血作用的牦牛皮胶原蛋白海绵及其制备方法和应用 |
US11744922B2 (en) * | 2017-10-27 | 2023-09-05 | Saint Louis University | Biomimetic sponges for tissue regeneration |
CN108525021B (zh) * | 2018-04-17 | 2021-05-18 | 山西医科大学 | 基于3d打印的含血管及毛囊结构组织工程皮肤及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1147258A (ja) * | 1997-07-30 | 1999-02-23 | Menicon Co Ltd | ゼラチンとコラーゲンとを含有する医用基材 |
JPH11319068A (ja) * | 1998-05-12 | 1999-11-24 | Menicon Co Ltd | 人工皮膚用基材およびその製法 |
WO2002091955A1 (fr) * | 2001-05-17 | 2002-11-21 | Kaneka Corporation | Rein artificiel presentant la fonction de metabolisme de proteine et son procede de fabrication |
WO2003092759A1 (fr) * | 2002-05-01 | 2003-11-13 | Japan Science And Technology Agency | Procede de preparation d'un materiau composite poreux |
JP2003325652A (ja) * | 2002-05-16 | 2003-11-18 | Gunze Ltd | 細胞組込型培養皮膚 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL105529A0 (en) * | 1992-05-01 | 1993-08-18 | Amgen Inc | Collagen-containing sponges as drug delivery for proteins |
AUPN174495A0 (en) | 1995-03-15 | 1995-04-06 | Ketharanathan, Vettivetpillai | Surgical prostheses |
JPH09122227A (ja) * | 1995-10-31 | 1997-05-13 | Bio Eng Lab:Kk | 医用材料およびその製造方法 |
CN1183972C (zh) | 1999-02-04 | 2005-01-12 | 吉林圣元科技有限责任公司 | 促进伤口组织修复的伤口覆盖材料 |
CN1141981C (zh) | 1999-02-04 | 2004-03-17 | 李校坤 | 促进脊髓组织损伤愈合的海绵材料其制备方法及应用 |
AUPR217300A0 (en) * | 2000-12-20 | 2001-01-25 | Ketharanathan, Vettivetpillai | Method of creating biological and biosynthetic material for implantation |
US20090312524A1 (en) * | 2003-11-28 | 2009-12-17 | Alternative Sourced Collagen, Llc | Compositions and methods comprising collagen |
CN1252251C (zh) | 2004-07-26 | 2006-04-19 | 戴育成 | 皮肤干细胞胶原海绵膜人工活性皮肤的制备方法 |
-
2005
- 2005-09-09 JP JP2005261840A patent/JP5008284B2/ja active Active
-
2006
- 2006-09-05 AU AU2006288336A patent/AU2006288336B2/en not_active Ceased
- 2006-09-05 BR BRPI0615905A patent/BRPI0615905B8/pt active IP Right Grant
- 2006-09-05 EP EP06797419.6A patent/EP1923078B1/en active Active
- 2006-09-05 CA CA2619785A patent/CA2619785C/en active Active
- 2006-09-05 CN CNA2006800326118A patent/CN101257933A/zh active Pending
- 2006-09-05 US US12/065,979 patent/US8889171B2/en active Active
- 2006-09-05 WO PCT/JP2006/317513 patent/WO2007029677A1/ja active Application Filing
- 2006-09-05 KR KR1020087007675A patent/KR101224927B1/ko active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1147258A (ja) * | 1997-07-30 | 1999-02-23 | Menicon Co Ltd | ゼラチンとコラーゲンとを含有する医用基材 |
JPH11319068A (ja) * | 1998-05-12 | 1999-11-24 | Menicon Co Ltd | 人工皮膚用基材およびその製法 |
WO2002091955A1 (fr) * | 2001-05-17 | 2002-11-21 | Kaneka Corporation | Rein artificiel presentant la fonction de metabolisme de proteine et son procede de fabrication |
WO2003092759A1 (fr) * | 2002-05-01 | 2003-11-13 | Japan Science And Technology Agency | Procede de preparation d'un materiau composite poreux |
JP2003325652A (ja) * | 2002-05-16 | 2003-11-18 | Gunze Ltd | 細胞組込型培養皮膚 |
Non-Patent Citations (3)
Title |
---|
KIMURA Y. ET AL.: "Adipose tissue engineering based on human preadipocytes combined with gelatin microspheres containing basic fibroblast growth factor", BIOMATERIALS, vol. 24, 2003, pages 2513 - 2521, XP004419996 * |
SASO Y. ET AL.: "Cell-preconfluent Baiyo Hifu eno Johosei bFGF Tenka Koka", JAPANESE JOURNAL OF BURN INJURIES, vol. 29, no. 1, 2003, pages 24 - 30, XP003009775 * |
See also references of EP1923078A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP1923078A4 (en) | 2011-12-14 |
CA2619785A1 (en) | 2007-03-15 |
JP2007068884A (ja) | 2007-03-22 |
AU2006288336B2 (en) | 2011-08-18 |
EP1923078B1 (en) | 2016-01-20 |
KR20080042151A (ko) | 2008-05-14 |
JP5008284B2 (ja) | 2012-08-22 |
AU2006288336A1 (en) | 2007-03-15 |
KR101224927B1 (ko) | 2013-01-22 |
US8889171B2 (en) | 2014-11-18 |
BRPI0615905A2 (pt) | 2011-05-31 |
CA2619785C (en) | 2013-12-03 |
CN101257933A (zh) | 2008-09-03 |
BRPI0615905B8 (pt) | 2021-12-07 |
EP1923078A1 (en) | 2008-05-21 |
BRPI0615905B1 (pt) | 2018-05-15 |
US20090143287A1 (en) | 2009-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5008284B2 (ja) | 組織再生用基材 | |
Ulubayram et al. | EGF containing gelatin-based wound dressings | |
Suzuki et al. | Experimental study of a newly developed bilayer artificial skin | |
Ruszczak | Effect of collagen matrices on dermal wound healing | |
Zheng et al. | Polydopamine-modified collagen sponge scaffold as a novel dermal regeneration template with sustained release of platelet-rich plasma to accelerate skin repair: a one-step strategy | |
De Vries et al. | Dermal regeneration in native non‐cross‐linked collagen sponges with different extracellular matrix molecules | |
US20020161440A1 (en) | Dermal scaffold using alkaline pre-treated chitosan matrix or alkaline pre-treated chitosan and alkaline pre-treated collagen mixed matrix | |
US9421229B2 (en) | Neural scaffolds | |
JP2020510701A (ja) | 創傷治癒薬 | |
JP3377354B2 (ja) | 人工皮膚 | |
WO2004052418A1 (ja) | 骨−軟骨組織の再生用移植体 | |
CN110025830B (zh) | 一种缓释抑菌型人工真皮模型及其构建方法 | |
JP2005211477A (ja) | 再生医療用支持体 | |
JP2022516123A (ja) | バイオロジカルスキャホールド及びその製造方法 | |
JP2003325652A (ja) | 細胞組込型培養皮膚 | |
CN102671243A (zh) | 一种负载季铵化壳聚糖/siRNA复合粒子的皮肤再生材料及其制备方法 | |
JP2014030663A (ja) | 徐放性組織再生材料 | |
RU2430743C2 (ru) | Биологически активное раневое покрытие | |
Jiang et al. | Improved wound healing in pressure-induced decubitus ulcer with controlled release of basic fibroblast growth factor | |
JPH08196618A (ja) | 細胞侵入性コラーゲン製剤、および人工皮膚、およびそれらの製造方法 | |
JP2000245450A (ja) | 生着率を改善する培養表皮用シート | |
JPH03242142A (ja) | 人工皮膚及びその製造方法 | |
JP4464056B2 (ja) | 発毛促進用複合材料 | |
JP2000262610A (ja) | 表皮再生を目的とした自家抜去毛包移植用の人工真皮 | |
Huang et al. | Wound dressings containing bFGF‐impregnated microspheres: Preparation, characterization, in vitro and in vivo studies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680032611.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006797419 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2619785 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006288336 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12065979 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/003254 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2028/DELNP/2008 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006288336 Country of ref document: AU Date of ref document: 20060905 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087007675 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0615905 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080310 |